Utility of B-type natriuretic peptide measurement in outpatients with heart failure with preserved ejection fraction;Utilidade do doseamento do peptídeo natriurético tipo B em doentes ambulatórios com insuficiěncia cardíaca com fracão de ejecão preservada

Revista Portuguesa de Cardiologia

Volumn 32, Issue 9, 2013, Pages 647-652

  Jorge, Antonio José Lagoeiro ^a   Di Calafiori Freire, Monica ^a   Luiz Ribeiro, Mário ^a   Fernandes, Luiz Cláudio Maluhy ^a   Lanzieri, Pedro Gemal ^a   Jorge, Bruno Afonso Lagoeiro ^a   Lage, João Gabriel B ^a   Rosa, Maria Luiza Garcia ^a   Mesquita, Evandro Tinoco ^a  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

B type natriuretic peptide; Diastole; Heart failure; Outpatients

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

AGED; ALGORITHM; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ELECTROCARDIOGRAM; FEMALE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TISSUE DOPPLER IMAGING;

B-TYPE NATRIURETIC PEPTIDE; DIASTOLE; DIÁSTOLE; DOENTES AMBULATÓRIOS; HEART FAILURE; INSUFICIÊNCIA CARDÍACA; OUTPATIENTS; PEPTÍDEO NATRIURÉTICO TIPO B;

AGED; CROSS-SECTIONAL STUDIES; FEMALE; HEART FAILURE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; OUTPATIENTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; STROKE VOLUME;

EID: 84888355010     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.repc.2012.10.019     Document Type: Article

References (29)

1. Schmidt MI, Duncan BB, Silva GA, et al. Doenças crǒnicas não transmissíveis no Brasil: carga e desafios atuais. The Lancet. 2011. http://dx.doi.org/10.1016/S0140-6736(11)60135-9.
2. Moutinho MAE, Colucci FA, Alcoforado V, et al. Insuficiěncia cardíaca com fracão de ejecão preservada e com disfuncão sistólica na comunidade. Arq Bras Cardiol. 2008;90:145-50.
3. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-9.
4. Tribouilloy C, Rusinaru D, Mahjoub H, et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J. 2008;29:339-47.
5. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective. J Am Coll Cardiol. 1995;26:1565-74.
6. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539-50.
7. Lubien E, DeMaria A, Krishnawamy P, et al. Utility of Btype natriuretic peptide in detecting diastolic dysfunction: Comparison with Doppler velocity recordings. Circulation. 2002;105:595-601.
8. Iwanaga Y, Nishi I, Furuishi S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure. J Am Coll Cardiol. 2006;47:742-8.
9. Cheung BMY. Plasma concentration of brain natriuretic peptide is related to diastolic function in hypertension. Clin Exp Pharmacol Physiol. 1997;24:966-8.
10. Ommen SR, Nishimura RA, Appleton CP, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation. 2000;102:1788-94.
11. Maisel AS, McCord J, Nowak RM, et al., Breathing Not Properly Multinational Study Investigators. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. J Am Coll Cardiol. 2003;41:2010-7.
12. Mottram PM, Leano R, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol. 2003;92:1434-8.
13. Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002;288:2144-50.
14. Lang MR, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79-108.
15. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-7.
16. Borlaug BA, Redfield MM. Are systolic and diastolic heart failure overlapping or distinct phenotypes within the heart failure spectrum? Circulation. 2011;123:2006-14.
17. Arques S, Jaubert MP, Bonello L, et al. Usefulness of basal B-type natriuretic peptide levels for the diagnosis of diastolic heart failure in young patients: an echocardiographic-catheterization study. Int J Cardiol. 2009. http://dx.doi.org/10.1016/j.ijcard. 2009.03.127.
18. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure - abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953-9.
19. Penicka M, Bartunek J, Trakalova H, et al. Heart failure with preserved ejection fraction in outpatients with unexplained dyspnea. JACC. 2010;55:1701-10.
20. Zuber M, Cuculi F, Jost CA, et al. Value of brain natriuretic peptides in primary care patients with the clinical diagnosis of chronic heart failure. J Scand Cardiovasc. 2009;26:1-6.
21. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012;33:1787-847.
22. Fuat A, Murphy JJ, Hungin AP, et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract. 2006;56:327-33.
23. Yamamoto K, Burnett Jr JC, Bermudez EA, et al. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail. 2000;6:194-200.
24. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349-53.
25. Krishnaswamy P, Lubien E, Clopton P, et al. Utility of Bnatriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med. 2001;111:274-9.
26. Kelder JC, Cowie MR, McDonagh TA, et al. Quantifying the added value of BNP in suspected heart failure in general practice: An individual patient data meta-analysis. Heart. 2011;97:959-63.
27. Kelder JC, Cramer MJ, Verweij WM, et al. Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure. J Card Fail. 2011;17:729-34.
28. Gustafsson F, Steensgaard-Hansen F, Badskjaer J, et al. Diagnostic and prognostic performance of N-terminal proBNP in primary care patients with suspected heart failure. J Card Fail. 2005;11:S15-20.
29. Nielsen OW, Rasmussen V, Christensen NJ, et al. Neuroendocrine testing in community patients with heart disease:Pplasma N-terminal proatrial natriuretic peptide predicts morbidity and mortality stronger than catecholamines and heart rate variability. Scand J Clin Lab Invest. 2004;64:619-28.